Cession d'une gamme de produits non essentiels
Viohalco-Hellenic Copper and Aluminum Industry SA
€0.00
16:00 25/11/14
4 Avril 2024
ECO Animal Health Group plc
(« ECO » ou la « Société »)
Cession d'une gamme de produits non essentiels
Disposal streamlines ECO Animal Health's product and pipeline focus
ECO Animal Health Group plc (AIM : EAH), une société mondiale de santé animale en croissance rapide avec un portefeuille de produits vétérinaires commercialisés et un pipeline de R&D exclusif en pleine maturité, aujourd'hui announces the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy ("ACME"), its long-term manufacturing partner, for a total consideration of €1.3m.
Continuing to streamline the business
ECO is focused on treatment and prevention of disease in pigs and poultry. ECOmectin® Horsepaste is a branded treatment for equine parasites based upon the ivermectin active ingredient and has for some time been non-core to the business.
La transaction
ACME has acquired all the marketing authorisations held by ECO for the ECOmectin® Horsepaste, together with the intellectual property, manufacturing and distribution arrangements and existing inventory ("the Transaction"). The marketing authorisations are principally within the UK and EU. In addition, ACME has been granted a trademark licence to market and sell the horse paste under the ECOmectin® brand.
The total consideration for the Transaction is €1.3m; €500,000 was paid on signature of the sale and purchase agreement with an undertaking to pay two further payments of €400,000 each on the date which is 18 months after completion and 36 months after completion. These two elements of deferred consideration are unconditional and supported with a bank guarantee which will be put in place within 45 days.
The revenue derived from this business in the year ending 31 March 2024 was £814,000 (2023 £988,000).
Reinvesting to support our pipeline
The Board believes that the Transaction further streamlines ECOs focus on its core species of pigs and poultry and in particular on developing its highly innovative pipeline of vaccines and preventatives. It is intended that the funds received from the Transaction will be invested in research and development to support new product development.
David Hallas, PDG d'ECO Animal Health Group plc, a commenté: "The disposal of ECOmectin® Horsepaste is in line with our stated intention of focusing on treatments and preventatives in pigs and poultry and this enables us to increase investment in our R&D pipeline. The brand and the broader business is a good fit for ACME Drugs S.r.l and we are pleased that the business will be taken forward by a committed owner.
"We continue to look for value accretive opportunities both within our portfolio and outside and for opportunities to reinvest in our R&D pipeline to support future growth."
-Prend fin-
Pour de plus amples informations s'il vous plaît contacter:
|
À propos d'ECO Santé Animale
ECO Animal Health est un leader mondial de la santé animale, développant et commercialisant des produits pharmaceutiques vétérinaires de marque à l'échelle mondiale, avec une expertise dans les antibiotiques et les vaccins pour les porcs et la volaille. Nous disposons d’un pipeline de R&D exclusif en pleine maturité.
Basés au Royaume-Uni, avec des bureaux mondiaux comprenant la R&D et la fabrication, nous disposons d'autorisations de commercialisation dans plus de 70 pays et employons plus de 200 personnes dans le monde.
Notre produit phare, Aivlosin®, est un médicament exclusif et breveté efficace contre les maladies respiratoires et intestinales chez les porcs et les volailles.
Cliquez ici pour plus d'informations : https://ecoanimalhealth.com
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.